Kindeva Drug Delivery announced today that it appointed David Stevens as its global chief commercial officer (CCO). Stevens’ role includes spearheading the commercial, business development and R&D activities for Kindeva. He aims to ensure continued growth, expansion and innovation from the drug delivery device contract development and manufacturing organization (CDMO). “David brings a breadth of […]
Contract Services
Stevanato Group, Owen Mumford to collaborate on Aidaptus auto-injector
Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology. Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with […]
TriMas completes purchase of Omega Plastics
TriMas (NASDAQ: TRS) announced today that it has completed its acquisition of medical device components maker Omega Plastics. The financial terms of the deal were not disclosed. Omega (Clinton Township, Michigan) expects to bring in $18 million in revenue in fiscal year 2021. Omega Plastics boasts core injection molding capabilities, an ISO Class 8 clean […]
Fareva, ApiJect ink 10-year licensing agreement on fill-finish production lines
Fareva and ApiJect Systems today announced a licensing agreement to fill-finish more than 500 million injectable drug doses per year. Under the agreement, Fareva intends to invest more than $56.5 million to install three blow-fill-seal production lines with support from the Government of France through the France Relance industry initiative, as well as the Investments […]
Baxter bolsters fill-finish capabilities with $100M investment in Germany
Baxter International (NYSE:BAX) plans to invest roughly $100 million to expand a sterile fill-finish manufacturing plant in Halle/Westfalen, Germany. BioPharma Solutions (BPS), a subsidiary of Deerfield, Illinois–based Baxter, will manage the new facility. BPS supports pharmaceutical companies through a range of offerings, including scientific support, sterile contract manufacturing and parenteral delivery systems. Get the full […]
BD breaks ground on pre-filled syringe manufacturing plant in Spain
BD (NYSE:BDX) announced today that it broke ground on its $200 million pre-filled drug delivery device manufacturing plant in Spain. Franklin Lakes, New Jersey-based BD announced in May that it would build the $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, with expectations of creating up to 600 jobs at the facility by 2030. […]
World faces a shortage of up to 2 billion COVID-19 vaccine syringes
The World Health Organization (WHO) reportedly warned that a massive shortage of syringes for COVID-19 vaccines could be on the horizon. Reuters reported that WHO expert Lisa Hedman told a United Nations briefing that the potential shortage of 1 billion to 2 billion syringes could slow down routine immunizations and create issues with needle safety […]
Phillips-Medisize expands its global manufacturing capacity
Phillips-Medisize announced today that it expanded its global manufacturing capacity through several collaborations and internal initiatives. Hudson, Wisconsin-based Phillips-Medisize, a Molex company, said its global reach now encompasses 36 world-class facilities with scalable, end-to-end capabilities tailored to help customers bring products to market quickly and efficiently from anywhere in the world. Get the full story […]
New BD syringe manufacturing lines are up and running in Nebraska
BD (NYSE:BDX) announced today that it increased its manufacturing capacity and domestic supply for syringes and needles. Franklin Lakes, N.J.-based BD’s new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent BD’s partnership with Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR). In July 2020, […]
Xeris, Tetra Pharma enter $71M licensing agreement for glucagon injection
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes […]
